UK AGM, EGM Calendar |
Tuesday, February 3 |
Redhall Group |
Gulfsands Petroleum |
Dewhurst |
Finsbury Growth & Income Trust |
UDG Healthcare |
Aberdeen Asset Management |
Numis Corporation |
Invesco Perpetual Enhanced Income |
Wednesday, February 4 |
Impax Asset Management Group |
Future |
Grainger |
Conygar Investment Trust |
Connect Group |
Victrex |
Daily Mail and General Trust |
Asia Resource Minerals |
Thursday, February 5 |
Enterprise Inns |
Compass Group |
Patisserie Holdings |
Frontera Resources |
Sunrise Resources |
Dunedin Smaller Companies Investment Trust |
GW Pharmaceuticals |
Friday, February 6 |
LED International |
Shaftesbury |
Salamander Energy |
Ophir Energy |
Monday, February 9 |
Kofax |
4D Pharma |
Scientific Digital Imaging |
Copyright 2015 Alliance News Limited. All Rights Reserved. |
IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial
4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed that a greater amount of patients receiving the drug than those receiving placebo experienced a reduction in asthma control questionnaire scores. Reports that a greater proportion of the MRx-4DP0004 group than the placebo group experienced a reduction in the total weekly use of rescue medication at all time points. Adds that 50% of patients receiving the drug experienced "clinically meaningful" improvements in asthma quality of life questionnaire scores. Says MRx-4DP0004 is progressing to part B of the trial. Plans to enrol asthma patients with more symptomatic disease. Expects this to give a greater scope for treatment effects to be observed.
Read more